Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (January 2026)
48 slides from Nasus Pharma's investor presentation, Jan 20, 2026
Slide 1: A New Frontier in Intranasal Drug Delivery
NAgus ANEW FRONTIERIN | INTRANASAL DRUG DELIVERY: Aclinical-stage pharmaceutical company s leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exc NYSE American Company Presentation - January 2026
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company’, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Address Medical Emergencies via Intranasal Drug Delivery NS002 was designed to address Use of well-known active limitations of injectable pharmaceutical ingredients Epinephrine, with a needle-free, Proprietary Nasax powder technology aims to enhance
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Addressing Significant Medical Emergencies DrugCandidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Pivotal study Epinephrine Anaphylaxis expected to initiate Q42026 Ondansetron Nausea and Vomiting FIH
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster Liquid formulation a (= * -"® < Less surface adhesion Pooling and runoff into nasopharynx Variable droplet size Slower, less predi
Slide 6: NS002: Intranasal Epinephrine
NS002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in~1% of cases" The standard of care for anaphylaxis is Epinephrine - this is typically self-administered via an Epinephrine auto-injector (EAl) or given via intramuscular (IM) injection by a healthcare p
Slide 8: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine Autoinjectors' with a 12-18 month shelf-life TT The proposed solution: NSO02 (open ities: Product candidate aims to offer aneedle-free solution, longer shelf-life, easily administered Large and bulky to carry? E by trained profes
Slide 9: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis 0, i 2 og Warners the cabal nonulston! ©'¥Fcj=}) Global Epinephrine market in 2024+ ‘9, 40M Patients with type 1 allergies in the U.S.> +6.5% From 2010 to 2023% CAGR t -20m J Patients experience severe type | +1
Slide 10: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA + Following FDA guidance based on the 505(b)(2) regulatory pathway + Demonstration of comparable PK/PD to EpiPen® only requirement for regulatory approval + Pivotal trial expected to initiate Q4 2026 + Short and cost-effective clinical development ° poor: nsooz @ Initiate
Slide 11: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine Orexo? Aquestive® ‘ARS Pharma’ (Market Cap (Market Cap (Market Cap $1.0887) seK1.1684) $403.8M*) PK Parameters Neffy (nasal spray) ween ANAPHYEM Commercial {nasal powder) —_ (sublingual) Clinicat NDA fi
Slide 12: Progression of Anaphylaxis + Epinephrine Onset of Action
Progression of Anaphylaxis + Epinephrine Onset of Action A Medical Emergency Where Every Second Counts and Speed Matters ARS-1 Neffy Nasus FMX1002 Tmax = 30 min? Tmax = 10 min? > ie) Smin 10min 15min 20min 25min 30min Time of Drug Administration ww MINUTES @ isminutes ‘. 15-30 MINUTES Type 1 Severe
Slide 13: NP002: Pilot Study
NA epuAR MA NSo002: NPOO2: PILO
Slide 14: NP002: NS002 Pilot Study Overview
NP002: NS002 Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) yy Screening: positive to skin allergen test Period 1 Pe
Slide 15: NP002: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
NPOO2: Faster, Higher and Sustained Absorption in Cri ical Therapeutic Window Pilot Study Pharmacokinetics (PK) 700 600 500 & Plasma epinephrine — 2 400 > £piPen 0.3 geometric mean -60 min. 4 ~*-Nasus 1.6mg - = 300 -e-Nasus 1.6mgtAllergen challenge net2 i see Sine #200 -s-Nasus 3.2mgtAllergen challe
Slide 16: NS002 vs. EpiPen: Shorter Tmax and T100 and Higher Absorption
NS002 vs. EpiPen®: Shorter Tmax and T100 and Higher Absorption Pilot study PK - baseline corrected 20.00 15.00 10.00 5.00 0.00 50 40 30 20 10 00 1100 (min NASUS Tmax median (min.) 16.50 2.00 8.98 * . | i Ez 1.6mgrAllergic 3.2mgrAllergic challenge challenge ‘7100 pg/mL (minutes) median N=12 as | oe K
Slide 17: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Pilot study pharmacodynamics (PD) Systolic Blood Pressure N=12 3 -e-£pipon — = Nasus 1.6mgnormat condition —e None 16mgattergenc chatonge —eNesus 3. 2mgattrgonic challenge Time trom administration (h) Heart Rate n=12 98 Sep
Slide 18: NP006: Phase 2 Single Dose Study
NA epuAR MA NS002: NPOO6: PHASE 2 SINGLE DOSE STUDY
Slide 19: NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability of Single Dose
NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability of Single %& 1 week é 1 week A Arm 1: N=6 B c aa Nasus spray 3.6mg Nasus spray 4.0mg in one nostril in one nostril Screening 12 healthy volunteers, age 18-55 & c Nasus spray 3.6mg eapere Nasus spray 4.0mg Arm 2: in one nostril in
Slide 20: More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen® NPOO6 Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects Comparison of Plasma Epinephrine (baseline adjusted) in Healthy Volunteers - Geometric Proportion of subjects achieving clinical threshold of 100pg/mL a
Slide 21: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen®: Higher Cmax, Shorter Tmax and T100 Phase 2 Results - Cmax, Tmax and T100pg/mL. =" T100pg/mL dian, ites) n=12 Cmax (Geometric mean + SD) n=12 Tmax (median, minutes) n=12 pg/mL (median, minutes) 1400 16 7 10 . 8 9 1200 4 8 = 1000 = @ w 9: § E10 — € = 00 = gs 3 : 8 é Es ;
Slide 22: NS002 Achieved Higher Absorption vs. EpiPen in the Critical Therapeutic Window
NS002 Achieved Higher Absorption vs. EpiPen® in the Critical Therapeutic Window Phase 2 PK results 2 re Mean AUCO-4min +SD n=12 Mean AUCO-10min +8D n=12 2 . else 2 © 50,99 Ge Bo) abe Mean AUCO-20min +SD N=12 Mean AUCO-30min +SD n=12 z . r 1.42 3 ] 159.89 bai i» 11879 097 H ° 2 NASUS None ottne stusi
Slide 23: NP006: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NPOO6: NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Systolic Blood Pressure n=12 Heart Rate n=12 Phase 2: PD results . systoli ° 20 40 6 20 100 120 2 a . —~EpiPen Time (rin) Time (enn) Respiration Rate n=12 Diastolic Blood Pressure n=12 fespiration Rate n: ——Nasus 3.6m
Slide 24: NP006: Results Summary
NPOO6: Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors, with Faster, Greater and Well-Tolerated Epinephrine Delivery NS002 reached the Epinephrine therapeutic plasma threshold faster than EpiPen® with transie! No findings at nasal examinations No serious adverse
Slide 25: NP007: Phase 2 Repeated Dose and Nasal Allergic Challenge Study
NASUS epuAR MA NSo02: NPOO7: PHASE 2 REPEATED DOSE AND NASAL ALLERGIC CHALLENGE STUDY
Slide 26: Study NP007: Designed to Compare Bioavailability, PK, PD and Safety
Study NP007: Designed to Compare Bioavailability, PK, PD and Safety of Single and Repeat Dosing with and without Nasal Allergic Challenge (NAC) rs & j = Interim analysis i Week’ de P Wook Nasal aller bose & 4 I AS ns002 dmg challnes. LiL moet 2aNS0024mg Group1 Week 2: Week 3: i] pina n=25 EplPen® 03
Slide 27: Study NP007 Strengthens NS002's Potential to be Best in Class
Study NP007 Strengthens NS002’s Potential to be Best in Class Study confirms prior PK and safety findings, further demonstrating attributes of nasal powder technology: Rapid and high absorption of Epinephrine. Ns002 demonstrated faster absorption: * Shorter Tmax and T100. + 91% of participants achie
Slide 28: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
Faster, Higher and Sustained Absorption in Critical Therapeutic Window Single dose results: Geometric mean +SE, 0.Shr a z 3 = H | Hl =| : = —*A. NAC + IN spray g 28. EpiPen é -*-C. IN spray, normal conditions Time (min.) NASUS 28
Slide 29: NS002 Demonstrates Favorable PK vs. EpiPen
NS002 Demonstrates Favorable PK vs. EpiPen® Geometric mean plasma epinephrine concentration over time: NP007 Ph2 interim analysis oe Nasus (4mg) x1 ONAC+ Nasus (Ame) x1 —eEpiPen xt Plasma Eipnephrine (pg/ml) Time (min.) 29
Slide 30: Neffy PK vs. EpiPen
Neffy® PK vs. EpiPen®* Neffy®’s Published Pharmacokinetic Data from FDA Approval Materials** Epinephrine Geometric Mean Concentration-Time Profiles Fy 2ARS-12 me with challenge (N=33) 2 ARS-12 me without Challenge (N=36) ‘Adrenalin 0.3 me (N=33) + Adrenalin me 1) a ree | Ey § § Plasma Concentration
Slide 31: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen® : Higher Cmax, Shorter Tmax and T100 Cmax (pg/ml) Tmax (min.) T100 (min.) Geometric mean median median 16 20 é as ‘800 4 301 7 3 700 e450 e 108 25 om * Zz 503.03 ini a_i = = q €2 2 £, z % 400 g Eas & Eig é 200 = : 1 = 053 100 2 “ss ° ° ° ALNACSINepray —B.EpiPen—_CINzpra
Slide 32: NS002 Achieved Higher Absorption than EpiPen in Critical Therapeutic Window
NS002 Achieved Higher Absorption than EpiPen® in Critical Therapeutic Window Comparison of AUC at 2.5-240 minutes 1000.0 1000 2 100 =A. NAC+ spray Geometric mean 2. EpiPen Geometric mean 20 ‘=®=C. IN spray, normal conditions Geometric mean 10 ‘uco-25min ‘AucoSmin ‘Auco-tomin AuCo-20min ‘AUCO-30min u
Slide 33: More Subjects Achieved Epinephrine Threshold with NS002 compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 compared to EpiPen® Proportion (%) who reached 100pg/mL 100 5 92.6 257 026 297 96.3 95.7 Proprtion reached 100pg/ml (%) 0 25 5 75 10 15 Time (min.) MEEA.NAC+IN spray lMMIC. IN spray, normal conditions «mB. EpiPen
Slide 34: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Median change from baseline - Systolic blood pressure (Single dose) ‘Median change (mm Hg) Median Change from baseline- Diastolic blood pressure (Single Dose) Change from baseline (mm Hg) 20 20 20 2A. NACE Nasus 4mg, 28. Epi
Slide 35: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Cont. Median change from baseline- Heart rate (Single dose) *-A.NAC# Nasus dmg —@=B. EpiPen —e=C. Nasus 4mg = 15 Baseline BPM (median): 3 NACHNasusxd —EpiPen asus xi & 76 75 3 2 2 Time (min.) é NASUS 35
Slide 36: Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption
Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption in a Dose Proportional Manner Normal conditions: NAC conditions: Geometric mean#SE, 0.5hr Geometric meansSE, 0.Shr 3200 2000 = EpiPen *2 (YR) eco || OL EIPEN * 21) Hy eri nacein 210) ‘n-0=7£2.1N* 2 (4/8) normal conditions
Slide 37: NS002 Repeated Dosing vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Repeated Dosing vs. EpiPen®: Higher Cmax, Shorter Tmax and T100 ‘Cmax (pg/mL) ‘Tmax (min.) Geometric mean median g 923.13 168 lh to 831.47 s1}32 a W = i, 200 Y Y ; : aeea median ad 7 us E uu Fag: 087 aid oss . | Y), U Y naéuZ D.epiPen* 2(U/R) EL.IN* 2(Y/, EIN*2(YR, FLNACSING2 F2.NACHING2 ~U no
Slide 38: More Subjects Achieve Epinephrine Threshold with NS002 Compared EpiPen
More Subjects Achieve Epinephrine Threshold with NS002 Compared EpiPen® Time to reach 100 pg/mL (minutes) median Single dose Double dose EpiPen® pore Nasus x1 (risked) Nasus x2 EpiPen® x2 1.0 3.1 0.6-0.9 27 Subjects who reached 100 pg/ml within 60 minutes Single dose Double dose Time EpiPen® EpiPen®
Slide 39: Subject Achieving Epinephrine Threshold with Neffy
Subject Achieving Epinephrine Threshold with Neffy* Time to reach 100 pg/mL (minutes) median Single dose Double dose ARS “Neffy" ARS “Neffy*" x2 cd 7-9 Subjects who reached 100 pg/ml within 60 minutes Single dose Double dose Time _ = ARS “Neffy*” x2 (minutes) Aes tty YR R/R s 18% 25% 20% 10 55% 55%
Slide 40: NS002 Repeat Dosing Achieved Higher Absorption vs. EpiPen in Critical Therapeutic Window
NS002 Repeat Dosing Achieved Higher Absorption vs. EpiPen® in Critical Therapeutic Window AUC during first 10 minutes AUC at 20 and 30 minutes «0 350 co 300 z = 2” 2 g g 150 2 100 2 so ° ° —e— 0. Epipen 2 (Y/R) Geometric mean 241.1 *2 (U/L), norma conditions Geometric mean = 21N*2(YR), normal condit
Slide 41: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Median change from baseline - Systolic blood pressure (Normal conditions) 20 a AO 0.EpiPen 2 (YR) em EL NAZI =O ER. E2.IN DIR) z wen ‘normal conditions: normal conditions Baseline mm Hg (median): E = Nasus x2 rg EpiPens2 Narusx2(t/i) T
Slide 42: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Cont. Median Change from baseli Change from baseline (mm Hg) 30 20 “0 \e- Diastolic blood pressure (Normal condi ns) = epiren 2 (YR) eet nz (YL) Time (min.) normal conditions Median Change from baseline- Diastolic blood pressure (NAC c
Slide 43: NS002 Repeat Dosing Tracks EpiPen and Kept Within Normal Limits Cont.
NS002 Repeat Dosing Tracks EpiPen® and Kept Within Normal Limits Cont. Median change from baseline- Heart rate (Normal conditions) 30 a eiren (ya) Omen INx2(t) = 0 = 82.£2.1Nx2IUR) = normal condtions normal condtons Baseline BPM (median): 5S x Hf EpiPena2 Nasusx2 (uy) NiveS? & 75 72 79 = = ° 20 ‘0 6
Slide 44: Study NP007 Demonstrates that NS002 is Well Tolerated after Single and Repeat Administration
Study NP007 Demonstrates that NS002 is Well Tolerated after Single and Repeat Administration (50 participants and 421 drug administrations) * No SAEs reported + NoCVAEs + Most AEs were local in nature and self resolving, with 95% mild and 5% moderate. + 1 participant discontinued due to eye pain. Ns
Slide 45: Robust Patent Portfolio
Robust Patent Portfolio Country Filed Patent No./ Publication No._| Grant Dato/ Pub. Date pert) 8/19/2018 | WO 2019/038756 A1 ‘National Phase entered 8/19/2038 China 8/19/2018 CN 110996912 A. 4/10/2020 Examination in progress: 8/19/2038 = en ae Sunes safennes ee oe eee eo ee a feed Country Filed | P
Slide 46: Proprietary Nasax powder technology designed to enhance intranasal drug absorption
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NS002 is needle-free, convenient, and easily administered; aiming to offer an alternative to Epinephrine autoinjectors and directly addressing the currently unmet need Multiple Phase 2 studies c
Slide 47: Leadership Team
Leadership Team Udi Gitboa, Co-Founder & Executive Chairman "Mr. Gilboa isa prominent sera life sclences entrepreneur and the co-founder of multiple medical device and ‘Bharmaceutical companies, He co founded and served aa director and CFO of BioBlast Ls (NASDAQ: ORPN), ‘Alcobra Ltd (NASDAQ: ADHD),
Slide 48: A New Frontier in Intranasal Drug Delivery
NAgus ANEW FRONTIERIN | INTRANASAL DRUG DELIVERY: Aclinical-stage pharmaceutical company s leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exc NYSE American